ライフサイエンスコーパス: Taxol

1 as well as clinical paclitaxel formulation (Taxol).

2 of antitumoral agents including paclitaxel (Taxol).

3 e source of the anti-cancer diterpenoid drug Taxol.

4 les and microtubules stabilized by GMPCPP or Taxol.

5 n and chemoresistance of MDA-MB-231 cells to Taxol.

6 e and is inhibited by anticancer agents like Taxol.

7 nfer resistance to antitumoral drugs such as Taxol.

8 in and mitoxantrone significantly but not to taxol.

9 s axons from degeneration in the presence of taxol.

10 Mcl-1 abundance, sensitizing cancer cells to Taxol.

11 h specific mitotic stress stimuli, including taxol.

12 sons, including nocodazole, vincristine, and Taxol.

13 mpaired by depletion of soluble tubulin with taxol.

14 ptosis and led to an increased resistance to Taxol.

15 ll uptake of immunotoxin by combination with Taxol.

16 MCAK and the mitotic checkpoint response to taxol.

17 ficient cells have a compromised response to Taxol.

18 t compromising the cytotoxic activity of the taxol.

19 well-established antimitotic agents such as taxol.

20 ign, culminating in a two-phase synthesis of Taxol.

21 otubules are absent but not against low dose taxol.

22 dazole treatment but an impaired response to Taxol.

23 he same region of the drug-binding pocket as Taxol.

24 tumors responsive to the anti-mitotic agent Taxol.

25 the biosynthetic correlation of melanin and Taxol.

26 r terpene synthesis can be used to arrive at Taxol.

27 ion is shown for access to the side-chain of taxol.

28 doubled the maximum tolerated dose (MTD) of Taxol.

29 response of cells to the microtubule poison Taxol.

30 43, both of which sensitized cancer cells to Taxol.

31 or therapeutic efficacy than that of NCM and Taxol.

32 ents (MSAs) and in human tumors resistant to Taxol.

33 bound the least amount of 2-(m-azidobenzoyl)taxol.

34 ly even in the presence of the MT stabilizer taxol.

35 to the level of fame justifiably accorded to Taxol (1) and its chemical siblings.

36 lators such as paclitaxel (originally called taxol; 1 muM), vinblastine (1 and 10 muM), colchicine (1

37 ds (1982), calicheamicin gamma(1)(I) (1992), Taxol (1994), and brevetoxin B (1995).

38 Taxol (a brand name for paclitaxel) is widely regarded a

39 cation of Drosophila larvae with paclitaxel (taxol), a chemotherapeutic agent that causes neuropathy

40 dase, but had limited effect on retention of Taxol, a 14-nm micelle form of PTX.

41 etic screen for mediators of the response to Taxol, a chemotherapeutic agent that stabilizes microtub

42 es; thus we evaluated it in combination with Taxol, a chemotherapeutic with activity in both diseases

43 Taxol, a first-line anti-tumour drug, has low effectiven

44 subpopulation disappears in the presence of Taxol, a microtubule stabilizing agent.

45 simulations indicated that the frequency of Taxol-accommodating conformations decreased dramatically

46 Taxol accumulates as part of a complex mixture of chemic

47 m a biomedical perspective to understand how Taxol added to these systems affects the mechanical prop

48 etrosynthetically guided access to synthetic Taxol, albeit in minute quantities and with enormous eff

49 e treated with the BrP-LPA alone (10 mg/kg), Taxol alone (10 mg/kg), or Taxol followed by BrP-LPA.

50 tium-labeled Taxol analog, 2-(m-azidobenzoyl)taxol, alone or in the presence of MSAs.

51 ttranslational modifications of tubulin with taxol also allows integrins into the proximal axon.

52 ization of microtubules by prior exposure to taxol also prevented the formation of DVs, consistent wi

53 ally important for the chemotherapeutic drug Taxol, an important anticancer agent and the only known

54 ifically photolabeled with a tritium-labeled Taxol analog, 2-(m-azidobenzoyl)taxol, alone or in the p

55 esistance to the chemotherapeutic compounds, Taxol and Actinomycin D, but higher susceptibility to th

56 We call microtubules in the presence of Taxol and another stabilizer, doubly stabilized.

57 were used for further media optimization for Taxol and Baccatin III production in five different liqu

58 Taxol and Baccatin III when quantified through competiti

59 ed inoculum and media selection for enhanced Taxol and baccatin III yields.

60 ni strain towards the enhanced production of Taxol and baccatin III.

61 rs, outperforming commercial paclitaxel drug Taxol and Cremophor EL formulated SB-T-1214.

62 Taxol and dimethyl sulfoxide promote rapid polymerizatio

63 information on the conformational effects of Taxol and discodermolide on microtubules isolated from c

64 ndicate complementary stabilizing effects of Taxol and discodermolide on the microtubules, which may

65 t cells ultimately satisfy the checkpoint in Taxol and do so faster at concentrations >0.5 microM.

66 Examples of high-value diterpenes are taxol and forskolin pharmaceuticals or ambroxide fragran

67 lymerization; unstable GDP-bound; and stable Taxol and GDP-bound.

68 Currently, cost-efficient production of Taxol and its analogs remains limited.

69 oposed as a prominent alternative source for Taxol and its intermediate Baccatin III, however the ver

70 ubculturing, rationalizing the decreasing on Taxol and melanin yields.

71 on differentiation, was in fact increased by taxol and nocodazole and normal in DW12.

72 Taxol and other antimitotic agents are frontline chemoth

73 Patients with Taxol and platinum-refractory recurrent ovarian cancer a

74 principle has come mainly from studies using taxol and related drugs to pharmacologically stabilize m

75 sitivity to the antiproliferative effects of Taxol and the FTI lonafarnib when used either as single

76 Microtubule-targeted agents such as Taxol and vincristine are prescribed widely for various

77 by examining the response of these cells to Taxol and Vinorelbine.

78 shed sensitivity to conventional agents (eg, Taxol and VP-16) but significantly increased susceptibil

79 of MTs stabilized by the taxane-site binders Taxol and zampanolide, and by peloruside, which targets

80 with a new fluorescent taxol donor, TAMRA-X-taxol, and kinesin derivatives with an acceptor fluoroph

81 inical evaluation of MV-NIS in patients with taxol- and platinum-resistant ovarian cancer.

82 At higher levels of Taxol, APC-deficient cells arrest as efficiently as wild

83 non-pathogenic fungi (endophytes) synthesize Taxol, apparently redundantly [2-7].

84 anisms underlying cancer cells resistance to Taxol are not fully understood.

85 However, the working mechanisms for Taxol are not fully understood.

86 bule-stabilizing agents, such as paclitaxel (Taxol), are effective chemotherapy drugs for treating ma

87 Here, using Taxol as a model system, we use nature's favored oxygena

88 e for generating a CoA ester of tiglic acid (Taxol B side chain), TmAAE3 and TmAAE13 as suitable for

89 ntibodies improved response to platinum- and Taxol-based chemotherapy.

90 in the HA gel), whereas Taxol-gel and other Taxol-based formulations left negligible amount of PTX i

91 not further decrease the tumor burdens than Taxol-based formulations, presumably due to the limited

92 ol (MAQC) data sets and pretreatment data on Taxol-based neoadjuvant breast cancer therapy from multi

93 ntually develop some degree of resistance to Taxol-based therapy.

94 is of the sequences of beta-tubulin near the Taxol binding site indicated that, in addition to the M-

95 mation on the structure of microtubules upon Taxol binding.

96 uside overrides the heterogeneity induced by Taxol binding.

97 The first committed step of Taxol biosynthesis in the Pacific yew (Taxus brevifolia)

98 We also engineered the next step in Taxol biosynthesis, a P450-mediated 5alpha-oxidation of

99 on re-triggering the molecular machinery of Taxol biosynthesis, their transcriptional factors, and/o

100 correlation with the molecular expression of Taxol biosynthetic genes.

101 Fascinatingly, the Taxol biosynthetic machinery and cellular acetyl-CoA of

102 xel, which is purportedly on the paclitaxel (Taxol) biosynthetic pathway.

103 We found that PB-Gly-Taxol bound the target protein beta-tubulin with both hi

104 of the chemotherapeutic compound paclitaxel (Taxol) bound in a central, occluded pocket.

105 ently solved atomic structure of paclitaxel (Taxol)-bound human P-gp.

106 d in feathers treated with 5-fluorouracil or taxol but not with doxorubicin or arabinofuranosyl cytid

107 are sufficient for a robust response against taxol, but cannot trigger CPC transfer from the chromoso

108 The significant reduction in SAC response to Taxol, but not nocodazole, coupled with the reduced bind

109 tumor-bearing mice significantly better than Taxol, but PPT-gel did not.

110 ient candidate for hexanoic acid activation (Taxol C side chain), and TmAAE4 as suitable candidate fo

111 oundation for an eventual total synthesis of Taxol capable of delivering not only the natural product

112 Pretreatment of wild-type platelets with taxol caused microtubule stabilization and phenocopied t

113 d the proliferation in HEY, A2780, and A2780/Taxol cells as evidenced by 3-(4,5-dimethylthiazol-2-yl)

114 Taxol chemotherapy is one of the few therapeutic options

115 vels in mammary tumors following paclitaxel (Taxol) chemotherapy.

116 y was to investigate the treatment effect of Taxol combined with Kanglaite on colorectal cancer cell

117 hibitors we studied the relationship between Taxol concentration, the DM, and the mitotic checkpoint.

118 ls are more sensitive to lower versus higher Taxol concentrations.

119 NMR and synthetic studies established the T-taxol conformation as the bioactive tubulin-binding conf

120 ity to whether or not they could adopt the T-taxol conformation.

121 the methods developed, we demonstrated that Taxol could improve SS1P penetration into tumors in para

122 r agents is an effective strategy to enhance Taxol cytotoxicity.

123 enzymes for the activation of butyric acid (Taxol D side chain), TmAAE13 as the best candidate for g

124 growth cones, very much like treatment with Taxol, demonstrating a potential link between MT dynamic

125 tes, including rhodamine 123 (Rh123) and the taxol derivative flutax-1.

126 a), the hydrogelator (5b), and hydrogel of a taxol derivative without compromising the cytotoxic acti

127 Taxol did not cause upregulation of vascular endothelial

128 We confirmed that, like Taxol, discodermolide binds to the taxane binding pocket

129 rase II (Topo II) drugs, whereas paclitaxel (Taxol) does not have this effect.

130 otubules were labeled with a new fluorescent taxol donor, TAMRA-X-taxol, and kinesin derivatives with

131 own apoptotic agents, such as staurosporine, taxol, doxorubicin, cisplatin and etoposide, utilized as

132 he choice of a drug-eluting stent (limus- vs taxol-eluting) in ITDM is controversial, with studies sh

133 The anticancer drug paclitaxel (Taxol) exhibits paradoxical and poorly understood effect

134 alone (10 mg/kg), Taxol alone (10 mg/kg), or Taxol followed by BrP-LPA.

135 osis after treatment with different doses of Taxol for 24 h.

136 S-O and SJSA), similar to the pharmaceutical Taxol formulation.

137 ndustrial value as biobased pharmaceuticals (taxol), fragrances (sclareol), food additives (steviosid

138 ng to C-5, C-10, and C-13) required to reach Taxol from taxadiene were accomplished.

139 culate PTX entrapped in the HA gel), whereas Taxol-gel and other Taxol-based formulations left neglig

140 Taxol (generic name paclitaxel) is a microtubule-stabili

141 reated with different stabilizers, including Taxol, guanosine-5' [(alpha, beta)-methyleno] triphospha

142 ctionalized intermediate in the synthesis of Taxol has been synthesized, which features the tricyclic

143 cy in suppressing tumor growth than clinical Taxol in a murine 4T1 breast cancer model, owing to prol

144 d a subsequent increase in the resistance to Taxol in cancer cells.

145 silvestrol, has shown activity comparable to taxol in certain settings.

146 zed, FOXO1-mediated, AR-inhibitory effect of Taxol in CRPC cells that may play an important role in T

147 The fungus sequesters Taxol in intracellular hydrophobic bodies that are induc

148 sistance to the microtubule-stabilizing drug Taxol in narrow confinement.

149 particles was over 9-fold lower than that of Taxol in P-gp-overexpressing cells.

150 ed tumor burden, and BrP-LPA was superior to Taxol in reducing blood vessel density in tumors.

151 eficiency compromises the arrest response to Taxol in vivo.

152 increased many cellular variations caused by Taxol, including tubulin polymerization, caspase-3 cleav

153 rotubules pharmacologically with paclitaxel (Taxol) increases pyroptosis without affecting the other

154 -sensitizes Snail-expressing cancer cells to Taxol, indicating that miR-125b is critical in Snail-ind

155 Paclitaxel (Taxol)-induced cell death requires the intrinsic cell de

156 Down-regulation of Bak1 suppressed Taxol-induced apoptosis and led to an increased resistan

157 Taxol-induced axonal degeneration in Drosophila shares m

158 that a pan-MLK inhibitor (CEP-11004) limited Taxol-induced cell death and that E(2) accentuated this

159 istant cells, causing a marked inhibition of Taxol-induced cytotoxicity and apoptosis and a subsequen

160 roteins in the cellular pathway that lead to Taxol-induced peripheral neuropathy, neuronal calcium se

161 sin-expressing macrophages protected against Taxol-induced tumor cell death in coculture, an effect f

162 Prolonged treatment with Taxol induces activation of calpain, degradation of NCS-

163 Taxol inhibits most of these conformational changes, all

164 ization of microtubules by pretreatment with Taxol inhibits osteoblast differentiation.

165 ing titers of taxadiene--the first committed Taxol intermediate--approximately 1 gram per liter (~15,

166 emotherapeutic agents, including paclitaxel (Taxol), involve pro-apoptotic ceramide in their anticanc

167 Taxol is a commonly used antitumor agent that hyperstabi

168 ggests that the failed arrest in response to Taxol is because of a specific defect in microtubule sta

169 riments determined that the binding site for Taxol is in a hydrophobic pocket in beta-tubulin, little

170 Second, since Taxol is often added to a number of cell types for thera

171 Paclitaxel (Taxol) is an effective chemotherapeutic agent for treatm

172 Paclitaxel (Taxol) is one of the most effective treatment options fo

173 The prototype of this group of drugs, Taxol, is an effective chemotherapeutic agent used exten

174 lar stabilization of syntelic attachments by Taxol itself appears responsible for accelerated checkpo

175 ues and a scalable laboratory preparation of Taxol itself.

176 low cytometry, we synthesized derivatives of Taxol linked to the drug-like fluorophore Pacific Blue (

177 Stabilizing the microtubules with taxol maintained the undulating geometry after injury bu

178 to therapeutic doses of the anticancer agent Taxol, making it an attractive novel therapeutic cancer

179 RPC cells that may play an important role in Taxol-mediated inhibition of CRPC growth.

180 colocalization with tubulin is enhanced upon Taxol-mediated microtubule stabilization, which, togethe

181 o uncouple the reorganizations, we have used taxol, nocodazole, and the specific GSK3-beta inhibitor

182 aite pretreatment may increase the effect of Taxol on colorectal cancer.

183 a mechanistic rationale to combine SS1P with Taxol or another cytotoxic drug as a strategy to increas

184 heterogeneous cancer cell lines relative to taxol or DDM; 3) reduced propensity for senescence induc

185 or long-term activity in cancer cells versus taxol or DDM; and 5) attenuation of metastatic character

186 le disrupting agent including nocodazole and taxol or release of mitotic shake-off cells into fresh m

187 o neuroblastoma cells that were treated with Taxol or vincristine inhibited activation of calpain and

188 In contrast, binding of either Taxol or zampanolide induces MT heterogeneity.

189 The attachment of a therapeutic agent (e.g., taxol) or a fluorophore (e.g., 4-nitro-2,1,3-benzoxadiaz

190 ful effort to replicate the beginning of the Taxol oxidase phase in the laboratory is reported, culmi

191 ized semisynthetic routes to next generation Taxol (paclitaxel) compounds could conceivably shorten t

192 Taxol (paclitaxel) is a potent anticancer drug first iso

193 Taxol (paclitaxel) is a very widely used anticancer drug

194 depletion of protein Daxx increases cellular taxol (paclitaxel) resistance-a common trait of patients

195 ver 350 members, the most famous of which is Taxol (paclitaxel), a billion-dollar anticancer drug.

196 Taxol (paclitaxel), a plant-derived anticancer drug, has

197 of this family is the polycyclic diterpenoid Taxol (paclitaxel), which promotes tubulin polymerizatio

198 amous for production of the anti-cancer drug Taxol (paclitaxel).

199 had superior anticancer efficacy relative to taxol, particularly in resistant models.

200 The antimitotic anti-cancer drugs, including taxol, perturb spindle dynamics, and induce prolonged, s

201 bule stabilizer paclitaxel (originally named taxol) precluded microplaque formation.

202 e report the results on our earlier reported Taxol-producing endophytic fungus, Fusarium solani from

203 Here we show that a Taxol-producing fungal endophyte, Paraconiothyrium SSM00

204 abolic engineering approaches for high-level Taxol production in cell cultures or microbial hosts.

205 bolic engineering efforts aimed at improving Taxol production in cell cultures.

206 fungus to be a novel platform for industrial Taxol production.

207 abolically stable A. terreus for sustainable Taxol production.

208 of A. terreus associated with attenuation of Taxol productivity, and their restoring potency upon coc

209 provide a novel conceptual framework for how Taxol prolongs mitosis and caution against using it in c

210 Finally, we report that Paclitaxel/taxol promotes mitotic rounding and subsequent entosis,

211 l stimulation of hind paws, in comparison to Taxol(R) administration at the same dose level that resu

212 rior anticancer efficacy to the conventional Taxol(R) formulation, but with significantly reduced sid

213 ro and in-vivo in comparison to the standard Taxol(R) formulation.

214 kin was lower in the L-PTX group compared to Taxol(R) group.

215 nd PTX, represents a superior replacement of Taxol(R) that mitigates the side effects associated with

216 hemotherapeutic drugs, including paclitaxel (Taxol(R)) and vincristine.

217 rmulating PTX with Cremophor EL and ethanol (Taxol(R)) realized its clinical potential, but the formu

218 the conventional solubilization formulation (Taxol(R)), but yielded less toxicity as indicated by the

219 Genexol-PM(R), permits dose escalation over Taxol(R), enhancing antitumor efficacy in breast, lung a

220 rs for injection, such as Cremophor EL(R) in Taxol(R).

221 dose escalation (Genexol-PM(R)) compared to Taxol(R).

222 Interestingly, the Taxol((R)) formulation showed higher antitumor activity

223 In comparison, treatment with Taxol((R)) resulted in toxicity issues as body weight de

224 rom silencing of molecular expression of the Taxol-rate limiting enzymes (GGPPS, TDS, DBAT and BAPT)

225 in 1 (XCLASP1) or treatment with the MT drug Taxol reduced axon outgrowth in spinal cord neurons.

226 ilization of midzone MTs with low amounts of Taxol rescues cytokinesis in INCENP actin-binding mutant

227 , the interaction between the development of Taxol resistance and miRNA has not been previously explo

228 ment of targeted therapeutics for overcoming Taxol resistance in a number of different tumor histolog

229 f1 elevates cyclin B stability and increases taxol resistance in cells and mouse xenograft models.

230 rt a central role for miR-125b in conferring Taxol resistance through the suppression of Bak1 express

231 xol sensitivity, overcoming miR-125-mediated Taxol resistance.

232 gated the role and mechanisms of miR-125b in Taxol resistance.

233 mpare the differentially expressed miRNAs in Taxol-resistant and their Taxol-sensitive parental cells

234 1, miR-222, and miR-923 were up-regulated in Taxol-resistant cancer cells by real-time PCR.

235 ctivated after antitubulin drug treatment in taxol-resistant cancer cells.

236 We found that miR-125b was up-regulated in Taxol-resistant cells, causing a marked inhibition of Ta

237 Further investigation of Daxx-mediated taxol response revealed that Daxx is important for the p

238 ving a possible relationship to platinum and taxol response.

239 siRNA sensitized B16F10 cells to paclitaxel (Taxol), resulting in a complete inhibition of tumor grow

240 xpressed miRNAs in Taxol-resistant and their Taxol-sensitive parental cells.

241 1 in miR-125b-overexpressing cells recovered Taxol sensitivity, overcoming miR-125-mediated Taxol res

242 the oncogenic transcription factor Myc as a taxol sensitizer.

243 that interferes directly with cell division (Taxol), showing its influence on cell organization and t

244 butyric acid (N-debenzoyl-N-(2-methylbutyryl)taxol side chain), TmAAE15 as a highly efficient candida

245 for esterification of benzoic acid with CoA (Taxol side chain).

246 l, we found that DSF/BKM in combination with Taxol significantly reduced the tumor burden and delayed

247 We show that when treated with Taxol, slippage-resistant HT29 colon carcinoma cells dis

248 Taxol slowed this loss by preventing tubulin depolymeriz

249 rotubules and prevented stomatal opening and taxol stabilized guard-cell microtubules and delayed sto

250 Bundles of taxol-stabilized microtubules (MTs)--hollow tubules comp

251 s region of the C-terminus of Nup98 and both Taxol-stabilized microtubules and the microtubule-depoly

252 nity of any fluorescently tagged protein for taxol-stabilized microtubules can be measured with this

253 Previous study of self-organization of Taxol-stabilized microtubules into asters in Xenopus mei

254 hods to determine the persistence lengths of taxol-stabilized microtubules.

255 Strikingly, we found that Taxol-stabilized MTs promote Tau filament formation with

256 em tau isoforms on the assembly structure of taxol-stabilized MTs.

257 h from straight to curved in the constituent taxol-stabilized tubulin oligomers, and the structure of

258 acts as an enhancer of depolymerization for taxol-stabilized tubulin.

259 lase, HDAC6, or stabilizing microtubules via Taxol stimulates IL-10 hyper-induction.

260 Importantly, this dose of Taxol strongly suppresses intestinal tumourigenesis in m

261 These endophytes, as well as pure Taxol, suppress fungal pathogens including wood-decaying

262 From menthol to cholesterol to Taxol, terpenes are a ubiquitous group of molecules (ove

263 why the duration of mitosis (DM) is less in Taxol than in nocodazole or Eg5 inhibitors we studied th

264 -spectrum anticancer drug paclitaxel (a.k.a. Taxol) that is stable in cell culture and labile to Pd c

265 rapeutics, such as rigosertib and paclitaxel/Taxol, that activate JNK through mitotic and oxidative s

266 nd that unlike for other spindle poisons, in Taxol the DM becomes progressively shorter as the concen

267 We targeted Taxol, the flagship taxane, as the upper limit of chemic

268 The ability of Taxol to alter microtubule formation was unchanged by th

269 n synergizes with the chemotherapeutic agent taxol to increase mitotic death, demonstrating that STAR

270 mately 1000-fold and reduces the toxicity of Taxol towards cancer cell lines by over 200-fold.

271 is believed to arrest mitotic progression in taxol-treated cells.

272 wide small interfering RNA (siRNA) screen in taxol-treated HeLa cells, we systematically identify com

273 Inhibiting the aurora-B kinase in Taxol-treated RPE1 cells accelerates checkpoint satisfac

274 den and delayed tumor recurrence compared to Taxol treatment alone.

275 In Drosophila, taxol treatment causes swelling, fragmentation, and loss

276 Stabilization of microtubules by taxol treatment did not stop elongation of cytochalasin

277 e AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.

278 on, detyrosination, and polyglutamylation by Taxol treatment or inhibition of glycogen synthase kinas

279 efect in microtubule stabilization following Taxol treatment rather than a general role of the APC pr

280 Kanglaite pretreatment followed by Taxol treatment was found to show the best synergism amo

281 After Taxol treatment, Nek4 promoted microtubule outgrowth, wh

282 When the forces are weakened by taxol treatment, the outer kinetochore expands radially

283 The effect was phenocopied by taxol treatment.

284 Senescence occurred following cisplatin- or Taxol-treatment in cell lines from both cancer types and

285 Microtubule perturbation by taxol (TX) and other microtubule-targeting drugs stalls

286 Notably, the drug taxol was found to exhibit a 184-fold decrease in activi

287 At the 10(th) subculture, the yield of Taxol was reduced by four folds (78.2 ug/l) comparing to

288 he M-loop in lateral stability in absence of taxol was shown to be minor.

289 8 days; P < .001), use of anthracyclines and taxols was lower (3.7% vs 5.0%; P < .001), and breast-co

290 ein, an efflux transporter known to detoxify taxol, were found to be elevated in the A2780TR cell lin

291 ells was unaffected following treatment with Taxol, whereas the viability of D54 cells was reduced by

292 However, as opposed to Taxol, which has major interactions with the M-loop, dis

293 Treatment with taxol, which suppresses microtubule dynamics and activat

294 0 mixture of Cremophor EL and ethanol, as in Taxol), while it is capable of maintaining the systemic

295 First, we ask whether Taxol will combine additively with another stabilizer or

296 By covalently connecting taxol with a motif that is prone to self-assemble, we su

297 Combining Taxol with cathepsin inhibition in vivo significantly en

298 The Taxol yield of A. terreus was drastically reduced with t

299 Attenuating the Taxol yield of A. terreus with the multiple-culturing an

300 Attenuating the Taxol yield of Aspergillus terreus with the subculturing